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Differential substrate specificity could be exploited 
 
In the August issue of TiPS, Epand and Lester analysed the effect of the 
physicochemical properties of the membrane on protein kinase C activity. In 
addition to those substrates discussed that require the presence of Ca2+ and 
phospholipids, other substrates can be phosphorylated in the absence of these 
activators. It is possible that this differential substrate requirement could be 
exploited pharmacologically. 
 
Three types of substrate have been characterized according to the nature of the 
activators (Ca2+, diacylglycerol and phospholipids) required for the 
phosphotransferase activity.  
- Substrates requiring Ca2+ and lipids which form a ternary complex with protein 
kinase C prior to phosphorylation, e.g. histone H1, troponin I, and > 80% of the 
cytosolic proteins from rat liver that are phosphoryiated by protein kinase C. 
- Substrates independent of Ca2+ but dependent on phospholipids, such as myelin 
basic protein and several lysine, serine or arginine copolymers. 
- Substrates independent of both Ca2+ and phospholipids, e.g. protamine and 
peptides containing the substrate sequence derived from protamine. 
 
In the latter case, direct interaction of protein kinase C with serine residues  
between extended basic sequences in protamine is sufficient to induce structural 
changes that unmask the catalytic site of protein kinase C. 
 
The complex reaction catalysed by protein kinase C offers the possibility of the 
development of a broad spectrum of inhibitors that may bind either to the catalytic 
site (e.g. isoquinoline, H7, staurosporine or K252 and pseudosubstrate peptides), 
or to the regulatory domain (e.g. sphingosine, phospholipid interacting drugs and 
aminoacridines). Combined with the different substrate specificities elicited by 
protein kinase C phosphorylation of physiological substrates, these chemically 
diverse agents may allow a useful definition of sets of inhibitors with potential 
pharmacological interests. For example, in the experimental model of twostep 
carcinogen-induced skin tumour promotion, staurosporine inhibited tumour growth 
but failed to prevent other phorbol diester-induced effects, such as oedema 
formation or epidermal hyperplasia, that were inhibited by quercetine; these 
differential effects were attributed to substrate-dependent specificity for 
staurosporine inhibition of protein kinase C. Similarly in cultured epidermal cells 
stimulated with phorbol diesters, H7 inhibited the rise in omithine decarboxylase 
activity, but failed to prevent the downregulation of EGF receptor, a process in 
which protein kinase C is involved. 
 
